Shenzhen - Delayed Quote CNY

Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ)

20.21
+0.74
+(3.80%)
At close: May 20 at 3:04:01 PM GMT+8
Loading Chart for 300122.SZ
  • Previous Close 19.47
  • Open 19.33
  • Bid 20.18 x --
  • Ask 20.19 x --
  • Day's Range 19.45 - 20.49
  • 52 Week Range 18.70 - 40.43
  • Volume 48,634,435
  • Avg. Volume 20,605,299
  • Market Cap (intraday) 48.378B
  • Beta (5Y Monthly) 1.29
  • PE Ratio (TTM) 183.73
  • EPS (TTM) 0.11
  • Earnings Date Apr 22, 2025
  • Forward Dividend & Yield 1.00 (4.95%)
  • Ex-Dividend Date Dec 25, 2024
  • 1y Target Est 35.23

Chongqing Zhifei Biological Products Co., Ltd. engages in the research, development, manufacture, marketing, distribution, import, and export of vaccines and biological products in China. It also provides cold storage services. The company was founded in 2002 and is based in Chongqing, China.

www.zhifeishengwu.com

7,220

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 300122.SZ

View More

Performance Overview: 300122.SZ

Trailing total returns as of 5/20/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

300122.SZ
23.16%
SSE Composite Index (000001.SS)
0.86%

1-Year Return

300122.SZ
39.73%
SSE Composite Index (000001.SS)
6.60%

3-Year Return

300122.SZ
64.51%
SSE Composite Index (000001.SS)
7.43%

5-Year Return

300122.SZ
59.46%
SSE Composite Index (000001.SS)
17.23%

Compare To: 300122.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 300122.SZ

View More

Valuation Measures

Annual
As of 5/20/2025
  • Market Cap

    48.38B

  • Enterprise Value

    60.42B

  • Trailing P/E

    190.30

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.84

  • Price/Book (mrq)

    1.58

  • Enterprise Value/Revenue

    3.54

  • Enterprise Value/EBITDA

    159.32

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    1.50%

  • Return on Assets (ttm)

    0.43%

  • Return on Equity (ttm)

    0.81%

  • Revenue (ttm)

    17.05B

  • Net Income Avi to Common (ttm)

    255.59M

  • Diluted EPS (ttm)

    0.11

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.07B

  • Total Debt/Equity (mrq)

    49.50%

  • Levered Free Cash Flow (ttm)

    -7.32B

Research Analysis: 300122.SZ

View More

Company Insights: 300122.SZ

Research Reports: 300122.SZ

View More

People Also Watch